1094873-17-2 Usage
General Description
JNJ 31020028 is a chemical compound developed by Johnson & Johnson with potential use in the treatment of several central nervous system disorders, including schizophrenia and major depressive disorder. It acts as a selective dopamine D4 receptor partial agonist, which suggests that it may help to regulate dopamine levels in the brain and thereby improve symptoms of these disorders. Early research on JNJ 31020028 has shown promising results in preclinical and clinical studies, indicating its potential as a novel therapeutic agent for these conditions. However, further research and clinical trials are needed to fully understand its safety and efficacy profile.
Check Digit Verification of cas no
The CAS Registry Mumber 1094873-17-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,9,4,8,7 and 3 respectively; the second part has 2 digits, 1 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1094873-17:
(9*1)+(8*0)+(7*9)+(6*4)+(5*8)+(4*7)+(3*3)+(2*1)+(1*7)=182
182 % 10 = 2
So 1094873-17-2 is a valid CAS Registry Number.
1094873-17-2Relevant articles and documents
The discovery and synthesis of JNJ 31020028, a small molecule antagonist of the Neuropeptide y Y2 receptor
Swanson, Devin M.,Wong, Victoria D.,Jablonowski, Jill A.,Shah, Chandra,Rudolph, Dale A.,Dvorak, Curt A.,Seierstad, Mark,Dvorak, Lisa K.,Morton, Kirsten,Nepomuceno, Diane,Atack, John R.,Bonaventure, Pascal,Lovenberg, Timothy W.,Carruthers, Nicholas I.
, p. 5552 - 5556 (2011/10/12)
A series of small molecules based on a chemotype identified from our compound collection were synthesized and tested for binding affinity (IC 50) at the human Neuropeptide Y Y2 receptor (NPY Y 2). Six of the 23 analogs tes
